Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 2, 2005, Pages 287-295

  Hu, Branda T ^a   Yu, Xinhong ^a   Jones, Thomas R ^a   Kirch, Carol ^a   Harris, Sarah ^a   Hildreth, Stephen W ^a   Madore, Dace V ^a   Quataert, Sally A ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN G; PNEUMOCOCCUS CAPSULAR POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; REAGENT; UNCLASSIFIED DRUG; OPSONIN;

ACCURACY; ADULT; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM IDENTIFICATION; EFFECTOR CELL; ENZYME IMMUNOASSAY; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOASSAY; INFANT; INTERNATIONAL CONFERENCE FOR HARMONIZATION GUIDELINE; METHODOLOGY; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; OPSONIZATION; OPSONOPHAGOCYTIC ASSAY; PERFORMANCE; PHAGOCYTOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; STANDARDIZATION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VALIDATION PROCESS; BLOOD; IMMUNOLOGY; PHAGOCYTE; STANDARD; VALIDATION STUDY;

ADULT; ANTIBODIES, BACTERIAL; HUMANS; IMMUNOASSAY; OPSONIN PROTEINS; PHAGOCYTES; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 22044448196     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.2.287-295.2005     Document Type: Article

References (41)

1. Anttila, M., M. Voutilainen, V. Jantti, J. Eskola, and H. Kayhty. 1999. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118:402-407.
2. Black, S. B., H. R. Shinefield, J. Hanse, L. Elvin, D. Laufer, and F. Malinoski. 2001. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20:1105-1107.
3. Bruyn, G. A. W., B. J. M. Zegers, and R. van Furth. 1992. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin. Infect. Dis. 14:251-262.
4. Butler, J. C., R. F. Breiman, J. F. Campbell, H. B. Lipman, C. V. Broome, and R. R. Facklam. 1993. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270:1826-1831.
5. Committee on Infectious Diseases. 2000. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106:362-366.
6. Concepcion, N., and C. E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal- polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8: 266-272.
7. de Haas, M. 2001. IgG-Fc receptors and the clinical relevance of their polymorphisms. Wien. Klin. Wochenschr. 113:825-831.
8. Fedson, D. S., and J. A. Scott. 1999. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17:S11-S18.
9. Food and Drug Administration. 2001. Guidance for industry: bioanalytical method validation. [Online.] http://www.fda.gov/cder/guidance/4252fnl.pdf.
10. International Conference on Harmonization. 1995. Guidance for industry: validation of analytical procedures. Document Q2A. [Online.] http://www .fda.gov/cder/guidance/ichq2a.pdf.
11. International Conference on Harmonization. 1996. Guidance for industry: validation of analytical procedures. Document Q2B. [Online.] http://www.fda .gov/cder/guidance/ichq2b.pdf.
12. Jansen, W. T. M., M. Vakevainen-Anttila, H. Kayhty, M. Nahm, N. Bakker, J. Verhoef, H. Snippe, and A. F. M. Verheul. 2001. Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine. Clin. Diagn. Lab. Immunol. 8:245-250.
13. Jodar, L., J. Butler, G. Carlone, R. Dagan, D. Goldblatt, H. Kayhty, K. Klugman, B. Plikaytis, G. Siber, R. Kohberger, I. Chang, and T. Cherian. 2003, Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21:3265-3272.
14. Johnson, S. E., L. Rubin, S. Romero-Steiner, J. K. Dykes, L. B. Pais, A. Rizvi, E. Ades, and G. M. Carlone. 1999. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J. Infect. Dis. 180: 133-140.
15. Kanayasu-Toyoda, T., T. Yamaguchi, E. Uchida, and T. Hayakawa. 1999. Commitment of neutrophilic differentiation and proliferation of HL-60 cells coincides with expression of transferrin receptor. J. Biol. Chem. 274:25471-25480.
16. Katyal, M., B. Sivasankar, S. Ayub, and N. Das. 2003. Genetic and structural polymorphism of complement receptor 1 in normal Indian subjects. Immunol. Lett. 89:93-98.
17. Kim, J. O., S. Romero-Steiner, U. B. Sorensen, J. Blom, M. Carvalho, S. Barnard, G. Carlone, and J. N. Weiser. 1999. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect. Immun. 67:2327-2333.
18. Kyaw, M. H., I. G. Jones, and H. Campbell. 2001. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health. Acta Paediatr. 90:473-476.
19. Marston, B. J., J. F. Plouffe, Jr., T. M. File, B. A. Hackman, S.-J. Salstrom, and H. B. Lipman. 1997. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. Arch. Intern. Med. 157:1709-1718.
20. Nahm, M. H., D. E. Briles, and X. Yu. 2000. Development of a multispecificity opsonophagocytic killing assay. Vaccine 18:2768-2771.
21. Ortqvist, A. 2001. Pneumococcal vaccination: current and future issues. Eur. Respir. J. 17:1282-1293.
22. Overturf, G. D., and The Committee on Infectious Diseases. 2000. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 106:367-376.
23. Peters, T. M., and K. M. Edwards. 2002. Pneumococcal vaccines: present and future. Pediatr. Ann. 31:261-268.
24. Puumalainen, T., N. Ekstrom, R. Zeta-Capeding, J. Ollgren, K. Jousimies, M. Lucero, H. Nobynek, and J. Kayhty. 2003. Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine. J. Infect. Dis. 187:1704-1708.
25. Quataert, S. A., C. S. Kirch, L. J. Quackenbush-Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590-597.
26. Rennels, M. B., K. M. Edwards, H. L., Keyserling, K. S. Reisinger, D. A. Hogerman, D. V. Madore, I. Chang, P. R. Paradiso, F. J. Malinoski, and A. Kimura. 1998. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101: 604-610.
27. Robinson, K. A., W. Baughman, G. Rothrock, N. L. Barrett, M. Pass, C. Lexau, B. Damaske, K. Stefonek, B. Barnes, J. Patterson, E. R. Zell, A. Schuchat, C. G. Whitney, and the Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network, 2001. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998. Opportunities for prevention in the conjugate vaccine era. JAMA 285:1729-1735.
28. Rodriguez, M. E., W.-L. van der Pol, L. A. M. Sanders, and J. G. J. van de Winkel. 1999. Crucial role of Fcγ RIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. J. Infect. Dis. 179:423-433.
29. Romero-Steiner, S., C. Frasch, N. Concepcion, D. Goldblatt, H. Kayhty, M. Vakevainen, C. Laferriere, D. Wauters, M. H. Nahm, M. F. Schinsky, B. D. Plikayti, and G. M. Carlone. 2003. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin. Diagn. Lab. Immunol. 10:1019-1024.
30. Romero-Steiner, S., D. Libutti, L. B. Pais, J. Dykes, P. Anderson, J. C. Whitin, H. L. Keyserling, and G. M. Carlone. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 4:415-422.
31. Soininen, A., M. Karpala, S. L. Wahlman, H. Lehtonen, and H. Kayhty. 2002. Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children. Clin. Diagn. Lab. Immunol. 9:1032-1038.
32. Stansfleld, S. K. 1987. Acute respiratory infections in the developing world: strategies for prevention, treatment and control. Pediatr. Infect. Dis. J. 6: 622-629.
33. 3 or 12-O-tetradecanoyl phorbol-13-aeetate. Leukemia Res. 22:537-547.
34. Tuomanen, E. I., R. Austrian, and H. R. Masure. 1995. Pathogenesis of pneumococcal infection. N. Engl. J. Med. 332:1280-1284.
35. van de Wetering, J. K., L. M. van Golde, and J. J. Batenburg. 2004. Collectins: players of the innate immune system. Eur. J. Biochem. 271:1229-1249.
36. Vidarsson, G., I. Jonsdottir, S. Jonsson, and H. Valdimarsson. 1994. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 170:592-599.
37. Vidarsson, G., S. T. Sigurdardottir, T. Gudnason, S. Kjartansson, K. G. Kristinsson, G. Ingolfsdottir, S. Jonsson, H. Valdimarsson, G. Schiffman, R. Schneerson, and I. Jonsdottir. 1998. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect. Immun. 66: 2866-2870.
38. Wernette, C. M., C. E. Frasch, D. V. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S. A. Quataert, S. Hildreth, D. J. Sikkema, H. Kayhty, I. Jonsdottir, and M. H. Nahm. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10:514-519.
39. World Health Organization. 1999. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. [Online.] http://www.who.int/emc-documents /meningitis/whocdscsredc997c.html.
40. World Health Organization. 2004. State of the art of new vaccines: research and development. [Online.] http://www.who.int/vaccine_research/ documents /new_vaccines/en/print.html.
41. World Health Organization Young Infants Study Group. 1999. Bacterial etiology of serious infections in young infants in developing countries: results of a multicenter study. Pediatr. Infect. Dis. J. 18:517-522.